Cytek Biosciences, Inc. provided earnings guidance for the year ended December 31, 2024. For the period, the company expects total revenue to be in the range of $203 million to $213 million, representing growth of 5% to 10% over the year ended December 31, 2023, assuming no change in currency exchange rates. Also, the company expects to report positive net income.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.85 USD | -2.01% | -5.59% | -36.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.03% | 784M | |
+10.25% | 226B | |
+13.64% | 198B | |
+17.64% | 142B | |
+29.00% | 111B | |
+2.09% | 65.26B | |
+14.43% | 54.36B | |
+6.68% | 50.94B | |
+8.05% | 44.8B | |
+3.13% | 36.8B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024